Syngene International Limited — Call Transcript 2021

Jan 18, 2021

==> picture [112 x 28] intentionally omitted <==

Ref: Syn/CS/SE/Reg 30/2020-21/Jan/85

Syngene International Limited

January 18, 2021

Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India T +91 80 6891 8000 F +91 80 6775 8808 CIN: L85110KA1993PLC01493 www.syngeneintl.com

To,The Manager,BSE LimitedCorporate Relationship DepartmentDalal Street,Mumbai – 400 001	To,The Manager,National Stock Exchange of India LimitedCorporate Communication DepartmentBandra(EAST),Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Subject: Intimation of Conference Call for Analysts and Investors

Dear Sir/Madam,

Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the intimation for conference call for Analysts and Investors to be held on Thursday, January 21, 2021.

The above-mentioned information will also be available on website of the Company www.syngeneintl.com.

Request to kindly take this intimation on record.

Thanking You,

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Digitally signed by PRIYADARSHINI MAHAPATRA DN: c=IN, o=Personal, PRIYADARSHIN 2.5.4.20=98524f9d9130962f80a142e6c4ee41de2a31ebbe4aca99a554bc2a1b35b665b0, postalCode=400607, st=MAHARASHTRA, serialNumber=df67e39aa5435d22f718c22d0516d97afb120 I MAHAPATRA 8536f4f1860285e06c72d0c9992, cn=PRIYADARSHINI MAHAPATRA ____________ Date: 2021.01.18 15:08:58 +05'30' Priyadarshini Mahapatra

Company Secretary and Compliance Officer

INVESTOR CONFERENCE CALL INVITE

Q3 FY 2020-21

==> picture [594 x 151] intentionally omitted <==

Syngene’s Q3 FY2021 Results Conference Call

At 03:00 pm IST on 21[st] January, 2021

The management team of Syngene International Limited (“Syngene”) will organize a conference call for Analysts and Investors on Thursday, 21[st] January at 03.00 pm IST following the announcement of financial results for the quarter ended December 31, 2020.

The call will be initiated with a brief management discussion on the Q3 FY2021 performance followed by an interactive Question & Answer session. Mr. Jonathan Hunt - Syngene’s Managing Director and Chief Executive Officer and other members of the senior management team will represent Syngene on the conference call.

Details of the conference call are as under:

Date:	Thursday, 21st January 2021
Time:	03:00 pm to 04:00 pm IST
Dial-in Numbers*
Primary Number	+91 22 6280 1279 / +91 22 7115 8180
Local Access Number	+91 70 4567 1221:Available all over India(Accessible from all carriers.)
International Numbers	•USA – 18667462133 (Toll Free) /+13233868721 (Toll)•UK – 08081011573 (Toll Free) /+442034785524 (Toll)•Singapore – 8001012045 (Toll Free) /+6531575746 (Toll)•Hong Kong – 800964448 (Toll Free) /+85230186877 (Toll)•Australia – 1800053698 (Toll Free)
Pre-registration Facility(Diamond_Pass_™link)	Step 1: Pre-register here.You will receive a passcode and a pin for thecall on the registered email address.Step 2: Dial into the call on the Conference Call date, enter the passcode& pin as prompted. You will be directly connected to the call

*When using dial-in numbers mentioned please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time

Syngene International: Putting Science to Work

Page 1

INVESTOR CONFERENCE CALL INVITE

Q3 FY 2020-21

==> picture [594 x 151] intentionally omitted <==

Replay Facility	Dial in numbers: +91 22 7194 5757 / +91 22 6663 5757Playback ID:46273The replay facility will be available from 21stJanuary 2021 till 28thJanuary 2021
Conference Call Transcript	Will be available within 7 working days of the call on the corporatewebsite:https://syngeneintl.com/

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene’s 4200 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing, at speed, to improve time-tomarket and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, BristolMyers Squibb and Herbalife, as well as 1.9 Mn sq ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading edge science as well as multinationals including GSK and Merck KGaA. For more details, visit https://syngeneintl.com/

For further information, please contact:

Krishnan G

Syngene International : +91 8068919807 :Krishnan.G@syngeneintl.com

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forwardlooking statements and/or based on management’s current expectations and beliefs concerning future developments and their potential effects upon Syngene and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.

Syngene International: Putting Science to Work

Page 2